Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Enochian Biosciences Inc (ENOB)

Enochian Biosciences Inc (ENOB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Renovaro BioSciences (NASDAQ: RENB) Releases CEO Shareholder Message Investor Brand Network - Wed Jan 17, 10:01AM CST

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released...

NVDA : 905.54 (-1.72%)
RENB : 1.4900 (+0.68%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Featured in Recent Proactive Interview Investor Brand Network - Mon Nov 27, 2023

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured...

RENB : 1.4900 (+0.68%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Releases Shareholder Letter Investor Brand Network - Tue Oct 3, 2023

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, is sharing a...

RENB : 1.4900 (+0.68%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube Investor Brand Network - Fri Sep 29, 2023

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has inked...

RENB : 1.4900 (+0.68%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials Investor Brand Network - Wed Aug 30, 2023

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released...

NVDA : 905.54 (-1.72%)
RENB : 1.4900 (+0.68%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Eyes Clear Path to IND Submission for Cancer Platform Investor Brand Network - Thu Aug 24, 2023

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application (“IND”) for its innovative Cancer Platform in...

RENB : 1.4900 (+0.68%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Discusses Product Development in Letter to Shareholders Investor Brand Network - Fri Aug 18, 2023

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), earlier this year issued a letter to shareholders from its CEO Mark Dybul, MD, in which Dr. Dybul discussed scientific and product development...

RENB : 1.4900 (+0.68%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies Investor Brand Network - Wed Aug 16, 2023

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent...

RENB : 1.4900 (+0.68%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB), GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer Investor Brand Network - Wed Aug 9, 2023

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, and...

INTC : 30.68 (-0.94%)
ORCL : 117.93 (-0.35%)
RENB : 1.4900 (+0.68%)
ENOB : 0.7000 (unch)
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm PR Newswire - Mon Sep 26, 2022

/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Enochian Biosciences,...

ENOB : 0.7000 (unch)

Barchart Exclusives

Should Amazon Stock Follow The ‘Magnificent 7’ Trend and Start Paying a Dividend? Barchart - 39 minutes ago
While fellow 'Magnificent 7' peers like Alphabet and Meta Platforms have recently initiated dividends, Amazon might not do so for at least the next couple of years. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot